---
title: "PE-22-28"
canonical_url: https://peptidelibrary.app/library/pe-22-28
description: "Shortened analog of spadin, a peptide derived from sortilin maturation, which blocks the TREK-1 potassium channel. Because mice lacking TREK-1 show a depression-resistant phenotype, the channel became an antidepressant target, and PE-22-28 produces antidepressant-like effects in rodents within days rather than the weeks required by monoamine reuptake inhibitors. Preclinical only, with no human trials, and not FDA-approved."
updated: 2026-11-07
publisher: Peptide Library
notice: "Research and educational use only. Not medical advice."
---

# PE-22-28

PE-22-28 (also called Spadin analog or TREK-1 blocker peptide) is a TREK-1 research peptide in the Neuromodulator class. PE-22-28 is a shortened analog of spadin, a peptide derived from the propeptide released when sortilin is matured. It blocks TREK-1, a two-pore-domain potassium channel encoded by KCNK2.

Shortened analog of spadin, a peptide derived from sortilin maturation, which blocks the TREK-1 potassium channel. Because mice lacking TREK-1 show a depression-resistant phenotype, the channel became an antidepressant target, and PE-22-28 produces antidepressant-like effects in rodents within days rather than the weeks required by monoamine reuptake inhibitors. Preclinical only, with no human trials, and not FDA-approved.

Also known as: Spadin analog, TREK-1 blocker peptide, GVSWGLR.

Categories: Cognitive, Experimental.

## Classification

- Type: TREK-1 research peptide
- Mechanism class: Neuromodulator
- Development stage: Research only
- Regulatory class: Research compound, not FDA-approved

## Mechanism

PE-22-28 is a shortened analog of spadin, a peptide derived from the propeptide released when sortilin is matured. It blocks TREK-1, a two-pore-domain potassium channel encoded by KCNK2. TREK-1 activity hyperpolarises neurons and dampens excitability, and mice lacking the channel show a depression-resistant phenotype, which is what made it a target. Blocking TREK-1 increases excitability of serotonergic neurons in the dorsal raphe and promotes hippocampal neurogenesis, producing antidepressant-like effects in rodents within days rather than the weeks required by monoamine reuptake inhibitors. The evidence is preclinical; no human trials have been published.

Targets: TREK-1 (KCNK2).

Origin: Synthetic GVSWGLR analog of spadin.

## Properties

- Sequence: GVSWGLR
- Length: 7
- Molecular formula: C35H55N11O9
- Molecular weight: 773.9 g/mol
- CAS number: 1801959-12-5

## Evidence

- Evidence level: Insufficient Evidence
- Highest documented: Lab & animal studies
- Human trials: 0
- Controlled human trials: 0
- Preclinical sources: 1
- Latest source: 2017

No human dose is established for this compound.

Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.

### Studies

1. Shortened Spadin Analogs Display Better TREK-1 Inhibition, In Vivo Stability and Antidepressant Activity. Front Pharmacol. 2017. 2017. Preclinical: in vitro (cells or tissue). Population: hTREK-1/HEK cells; mice in behavioural models and mouse cortical neurons. Reduced immobility time in the forced swimming test, shorter latency to eat in the novelty suppressed feeding test, and markers of neurogenesis and synaptogenesis; the authors report activity lasting up to 23 hours against 7 hours for spadin. Limitations: Lab or animal research: not evidence of a human effect or dose. [Source](https://pubmed.ncbi.nlm.nih.gov/28955242/)
2. First evidence of protective effects on stroke recovery and post-stroke depression induced by sortilin-derived peptides. Neuropharmacology. 2019. 2019. Preclinical: animal or lab study. Population: Mice with focal ischaemia and post-stroke depression. Less body weight loss and dopaminergic degeneration, better motor and cognitive scores, and prevention of post-stroke depression behaviour; the authors report that low doses activated TREK-1 and higher doses inhibited it. Research on a related compound, not this one. Limitations: Studied an analog, not PE-22-28 itself; Lab or animal research: not evidence of a human effect or dose. [Source](https://pubmed.ncbi.nlm.nih.gov/31325429/)

## Safety

Side effects: No established human AE profile.

Risks: Research-only.

Human safety basis: No controlled human safety data

Key limitations: No established human dosage.; No controlled human trial results in the reviewed sources.; Not approved by the FDA for any use..

## Regulatory status

PE-22-28 is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.

- FDA status: Not Approved
- Availability: Research-Only

## Frequently asked questions

### What is PE-22-28?

Shortened analog of spadin, a peptide derived from sortilin maturation, which blocks the TREK-1 potassium channel. Because mice lacking TREK-1 show a depression-resistant phenotype, the channel became an antidepressant target, and PE-22-28 produces antidepressant-like effects in rodents within days rather than the weeks required by monoamine reuptake inhibitors. Preclinical only, with no human trials, and not FDA-approved.

### How does PE-22-28 work?

PE-22-28 is a shortened analog of spadin, a peptide derived from the propeptide released when sortilin is matured. It blocks TREK-1, a two-pore-domain potassium channel encoded by KCNK2.

### Is PE-22-28 FDA approved?

No. PE-22-28 is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.

### What is the amino acid sequence of PE-22-28?

PE-22-28 has the sequence GVSWGLR. Its molecular formula is C35H55N11O9.

### What peptides are similar to PE-22-28?

Compounds most often compared with PE-22-28 include Delta Sleep-Inducing Peptide (DSIP), N-Acetyl Selank Amidate, Noopept and Orexin-A. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.

## References

- [Shortened Spadin Analogs Display Better TREK-1 Inhibition, In Vivo Stability and Antidepressant Activity — Front Pharmacol, 2017](https://pubmed.ncbi.nlm.nih.gov/28955242/)
- [Fighting against depression with TREK-1 blockers: Past and future. A focus on spadin — Pharmacol Ther, 2019](https://pubmed.ncbi.nlm.nih.gov/30291907/)
- [The Involvement of Sortilin/NTSR3 in Depression as the Progenitor of Spadin and Its Role in the Membrane Expression of TREK-1 — Front Pharmacol, 2018](https://pubmed.ncbi.nlm.nih.gov/30670975/)
- [Class-level evidence — Spadin as a new antidepressant: absence of TREK-1-related side effects — Neuropharmacology, 2012](https://pubmed.ncbi.nlm.nih.gov/21807005/)
- [Class-level evidence — Spadin Selectively Antagonizes Arachidonic Acid Activation of TREK-1 Channels — Front Pharmacol, 2020](https://pubmed.ncbi.nlm.nih.gov/32317978/)
